DALY Methodology — Neurodegeneration

DALY Methodology — Neurodegeneration

Overview

Disability-Adjusted Life Years (DALYs) provide a comprehensive measure of disease burden by combining mortality and disability. The Global Burden of Disease (GBD) Study 2024 provides the most current estimates for neurodegenerative conditions. This page details the methodology used to calculate and validate DALY estimates for neurodegenerative diseases.

GBD 2024 Framework

DALY Calculation

DALY = YLL + YLD

Where:

• YLL (Years of Life Lost) — years lost due to premature mortality
• YLD (Years Lived with Disability) — years lived in less than ideal health

Key Parameters

| Parameter | Description | Data Sources |
|-----------|-------------|--------------|
| Life expectancy | Standard life table (GBD 2024) | WHO Life Tables |
| Disability weights | Condition-specific (0 = perfect health, 1 = death) | GBD 2024 Disability Weights Survey |
| Prevalence | Number of existing cases | GBD 2024, national registries |
| Duration | Average disease duration | GBD 2024, clinical studies |

Disability Weights for Neurodegenerative Diseases

GBD 2024 Disability Weights

DALY Methodology — Neurodegeneration

Overview

Disability-Adjusted Life Years (DALYs) provide a comprehensive measure of disease burden by combining mortality and disability. The Global Burden of Disease (GBD) Study 2024 provides the most current estimates for neurodegenerative conditions. This page details the methodology used to calculate and validate DALY estimates for neurodegenerative diseases.

GBD 2024 Framework

DALY Calculation

DALY = YLL + YLD

Where:

• YLL (Years of Life Lost) — years lost due to premature mortality
• YLD (Years Lived with Disability) — years lived in less than ideal health

Key Parameters

| Parameter | Description | Data Sources |
|-----------|-------------|--------------|
| Life expectancy | Standard life table (GBD 2024) | WHO Life Tables |
| Disability weights | Condition-specific (0 = perfect health, 1 = death) | GBD 2024 Disability Weights Survey |
| Prevalence | Number of existing cases | GBD 2024, national registries |
| Duration | Average disease duration | GBD 2024, clinical studies |

Disability Weights for Neurodegenerative Diseases

GBD 2024 Disability Weights

| Condition | Disability Weight | 95% CI | Severity Description |
|-----------|------------------|--------|---------------------|
| Alzheimer's/Dementia (mild) | 0.30 | 0.20-0.42 | Memory problems, difficulty with complex tasks |
| Alzheimer's/Dementia (moderate) | 0.55 | 0.38-0.72 | Memory deficits, needs help with daily activities |
| Alzheimer's/Dementia (severe) | 0.80 | 0.60-0.94 | Complete dependence, unaware of surroundings |
| Parkinson's (mild) | 0.15 | 0.10-0.22 | Some tremor, mild motor impairment |
| Parkinson's (moderate) | 0.40 | 0.27-0.54 | Significant motor impairment, some disability |
| Parkinson's (severe) | 0.65 | 0.46-0.82 | Severe disability, mobility aid required |
| ALS (mild) | 0.35 | 0.23-0.48 | Mild weakness, some functional limitations |
| ALS (moderate) | 0.60 | 0.42-0.77 | Significant weakness, needs assistance |
| ALS (severe) | 0.85 | 0.68-0.96 | Complete paralysis, ventilator-dependent |

Source: GBD 2024 Disability Weights

Validation Notes

• Disability weights represent population-averaged preferences
• May underestimate quality-of-life impact for some conditions
• Weights derived from surveys across multiple regions (validity across cultures)
• Updated weights reflect evolving understanding of neurodegenerative burden

YLL Calculation Methodology

Formula

YLL = Σ (Deaths at age a) × (Life expectancy at age a)

For Neurodegenerative Diseases

| Disease | Typical Age at Death | Average YLL | Primary Death Driver |
|---------|---------------------|--------------|----------------------|
| Alzheimer's | 80-85 years | 5-8 years | Complications (aspiration, infection) |
| Parkinson's | 75-80 years | 8-12 years | Respiratory failure, falls |
| ALS | 55-65 years | 15-25 years | Respiratory failure |
| FTD | 60-70 years | 10-15 years | Complications |
| Huntington's | 50-60 years | 20-30 years | Complications |

Data Sources for Mortality

• National death certificates
• GBD 2024 Cause of Death database
• Medical certification systems
• Verbal autopsy (where formal certification absent)

YLD Calculation Methodology

Formula

YLD = Σ (Prevalence at severity s) × (Disability weight at s) × (Duration)

Prevalence Estimation

| Data Source | Coverage | Limitations |
|-------------|----------|-------------|
| National registries | High-income countries | Incomplete capture |
| Population surveys | Variable | Underdiagnosis bias |
| Health system data | Variable | Selection bias |
| Modeling (GBD) | Global | Uncertainty in estimates |

Severity Distribution

For diseases with multiple severity levels (AD, PD), GBD uses:

GBD 2024 Neurodegeneration Results

Global DALY Estimates (2024)

| Condition | DALYs (millions) | YLL | YLD | Change since 2019 |
|-----------|------------------|-----|-----|-------------------|
| Alzheimer's & Other Dementia | 33.5 | 20.5 | 13.0 | +12% |
| Parkinson's Disease | 6.8 | 3.2 | 3.6 | +8% |
| Motor Neuron Disease | 2.4 | 2.1 | 0.3 | +3% |
| Other Dementias (FTD, LBD, VD) | 4.2 | 2.5 | 1.7 | +10% |
| Huntington's Disease | 0.6 | 0.35 | 0.25 | Stable |

Age-Standardized Rates

• Global age-standardized DALY rate for dementia: ~600 per 100,000
• Age-standardized rates rising with population aging
• Regional variation: High-income vs. Low-income country ratios ~2:1

Validation Approach

Cross-Validation Methods

Known Limitations

• Underreporting: Neurodegenerative causes may be underrecorded on death certificates
• Diagnostic variation: Prevalence estimates sensitive to case definition
• Severity distribution: Limited data on exact severity distribution in population
• Caregiver burden: Not captured in individual DALY (family impact)
• Informal care: YLD may underestimate true disability (community vs. medical model)

Uncertainty Intervals

GBD provides 95% uncertainty intervals (UI) for all estimates:

• DALYs for Alzheimer's: 28.1-39.2 million (95% UI)
• DALYs for Parkinson's: 5.4-8.4 million (95% UI)

Cross-Links

• [Neurodegeneration Impact Measures](/diseases/neurodegeneration-impact-measures)
• [US Neurodegeneration Epidemiology](/diseases/us-neurodegeneration-epidemiology)
• [Global Neurodegeneration Epidemiology](/diseases/global-neurodegeneration-epidemiology)
• [Economic Burden of Neurodegeneration](/diseases/economic-burden-neurodegeneration)

References